Clinical Trials Logo

Clinical Trial Summary

Lichen planus is a chronic inflammatory dermatosis. It most often affects the skin and mucous membranes. Sometimes lesions may appear in the area of nails (estimated at 10% of patients) or genital organs and anus. The most dangerous form of lichen planus is lichen that develops on the oral mucosa. It is believed to be the cause of the development of oral cancer. The vast majority of people suffering from lichen planus - 90%, experience spontaneous resolution of symptoms within a maximum of two years from the moment of their onset. In about half of the patients, the changes disappear within about 6 months. People who have a problem that their ailments do not want to go away on their own must take into account the fact that treating lichen is not the easiest one. Treatment of lichen is mainly based on alleviating its symptoms and accelerating the resolution of symptoms. Topical ointments containing strong glucocorticosteroids are usually applied to skin lesions or we can use Photodynamic Therapy


Clinical Trial Description

Oral lichen planus is most often characterized by lesions resembling a painless white mesh, which is usually located on the inside of the cheeks and the sides of the tongue. Lumps, erosions or erythematous changes are less often noticeable. Symptoms in oral lichen planus are often: reddening, dry mouth baking, swelling and minor bleeding. Sometimes the gum mucosa exfoliates. When erosions occur, patients complain of pain and problems with drinking and swallowing food. Oral lesions necessarily require treatment. Since lichen planus comes in many forms, some of them require histopathological examination to identify some of them. These tests involve taking a slice of the affected skin and examining it under a microscope. Some causes of lichen planus are thought to involve several components. Medications: lichen planus can occur as a reaction to certain medications, including: beta-blockers, which are common drugs used to treat cardiovascular problems; anti-inflammatory drugs; injections to treat arthritis; antimalarial drugs; thiazide diuretics; phenothiazines, a group of tranquilizers with antipsychotic effects. A prospective, randomized, single-blind 12-week clinical trial of full contralateral split-mouth in patients with bilateral erythematous or erosive lichen planus in the mouth.On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy using toluidine blue in four sessions every 2 days. olp on the other side was treated with the administration of the steroid triamcinolone for 8 days The clinical evaluation of the evolution of OLP eruptions was performed within 12 weeks of qualifying for treatment: at baseline, at the end of both treatments (day 8) and after the next 11 weeks ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04976673
Study type Interventional
Source Wroclaw Medical University
Contact
Status Completed
Phase Phase 2
Start date December 10, 2020
Completion date May 22, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03320460 - Photobiomodulation in Oral Lichen Planus N/A
Completed NCT02276573 - Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus N/A
Recruiting NCT06158113 - Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study Phase 2
Completed NCT03687437 - Lichen Planus and Mean Platelet Volum
Completed NCT00130572 - Efficacy of Elidel Cream on Erosive Oral Lichen Planus Phase 3
Completed NCT04673916 - Treatment Protocols for Patients With Symptomatic Oral Lichen Planus N/A
Not yet recruiting NCT06362005 - The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus Phase 4
Completed NCT00133107 - Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus N/A
Completed NCT00102557 - Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus Phase 2
Completed NCT04718311 - Study on Treatment for Patients With Symptomatic Oral Lichen Planus N/A
Recruiting NCT05330572 - Clinical and Molecular Correlates of Response to First Line Treatment in Lichen Planus
Completed NCT00656214 - Treatmant of Oral Lichen Planus With Lycopene Phase 2
Completed NCT00746772 - Efficacy of Purslane in Treatment of Oral Lichen Planus Phase 2